Treats relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at…. Sold as Poteligeo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Mogamulizumab-Kpkc (sold as Poteligeo), first approved Aug 8, 2018, with 0 new uses approved and 0 published complete response letters.
| Poteligeo | Part B | $85.2M | +12% | 378 |
| Poteligeo | Part D | $3.5M | +89% | 0 |
| Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceMycosis Fungoides, Sezary Syndrome · Kyowa Kirin Co., Ltd. | — | Recruiting | Aug 20, 2025 |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaT Cell Lymphoma, T-cell Lymphoma · Yale University | Phase 2 | Recruiting | Aug 18, 2023 |
| Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasCutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome · University of Michigan Rogel Cancer Center | Phase 2 | Recruiting | Jul 21, 2023 |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell LymphomaFolliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · City of Hope Medical Center | Phase 2 | Recruiting | Jun 18, 2021 |
| Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/LymphomaRecurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · John Reneau | Phase 1 | Recruiting | Apr 19, 2021 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 8, 2018 | PoteligeoBLA 761051 · New molecular entity | Kyowa Kirin | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA